Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug

MT Newswires Live

10 hours ago

Racura Oncology (ASX:RAC) developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.

The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.

Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610967768"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610967768\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610967768?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 07:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610967768","market":"sg","top_or_hot":-1,"title":"Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug","media":"MT Newswires Live","content":"<html><body><p> Racura Oncology (ASX:RAC) developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.</p><p>The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.</p><p>Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Racura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRacura Oncology Develops Blood Test to Assess Potential of Proprietary Formulation of Anticancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-11 07:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Racura Oncology (ASX:RAC) developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.</p><p>The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.</p><p>Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2610967768","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610967768","pubTimestamp":1770765542,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Racura Oncology  developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","RAC.AU":"RACE ONCOLOGY LTD","BK7067":"生物科技"},"translate_title":"Racura Oncology开发血液测试以评估抗癌药物专有配方的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Racura Oncology (ASX:RAC) developed a blood-based molecular test to assess the potential of RC220, its proprietary formulation of bisantrene, a potent anticancer drug, to protect the heart from damage, according to a Wednesday filing with the Australian bourse.The blood test will quantify the protective effects of RC220 on the molecular pathways causing anthracycline cardiotoxicity, a side effect of chemotherapy, the filing said.Bisantrene has proven clinical efficacy in a range of solid tumor cancers with lower heart toxicity than other widely used chemotherapies, the company said in a statement.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}